|Bid price||0.00||Open price||0.00|
|Ask price||0.00||Prev close||31.00|
Register now for FREE live PuriCore share prices, PuriCore stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get PuriCore Level 2 Data, indepth research tools and investor commentary for PuriCore (PURI) and other London Stock Exchange equities.
Register now for FREE PuriCore share price charts
|Sector||Health Care Equipment & Services||ISIN||GB00B3XBCR18|
|Activites||PuriCore develops and commercializes proprietary products that safely, effectively, and naturally kill contagious pathogens including major public health threatsÂ—M.tuberculosis, MRSA, E.coli, norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and Legionella. Our products generate hypochlorous acid, the same natural anti-microbial produced by the human body to fight pathogens. Hypochlorous acid is highly effective in killing all types of bacteria, viruses, and fungal spores. PuriCore's technology and solutions are used in a broad range of markets that depend upon controlling contamination, including endoscopy, food retail, foodservice, hospitality, institutional, and wound therapy. Our antimicrobial solution is deployed as soaks, sprays, mists, and in other forms to limit the spread of infectious disease. The patented technologies use a simple combination of water, salt, and electricity to produce the same powerful solution found in the human immune system. PuriCore's highly sophisticated processes and controls allow the production of these unique biocidal solutions with a variety of different chemical and microbiological properties for use in specific settings and applications.||Index||n/a|
|Latest Share Price (p)||0.00||Net Gearing (%)||35.86|
|Market Capitalisation (£m)||15.54||Gross Gearing (%)||49.05|
|Shares in issue (m)||50.14||Debt Ratio||0.00|
|P/E Ratio||-2.39||Debt-to-Equity Ratio||0.00|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.96|
|Dividend Yield (%)||0.00||Price to book value||1.17|
|Dividend cover (x)||0.00||ROCE||-0.03|
|Earning per share (p)||-13.00||EPS Growth (%)||-225.00|
|52 week high / low||54.50 / 27.50||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
PuriCore has narrowed its FY pretax loss to $7.0m, from a loss of $8.6m. Revenue totalled $17.1m, from $31.5m. CEO Michael Ashton said: "This year represented a turning-point for PuriCore. We successfully completed the sale of our UK Endoscopy business for net proceeds of $25.6 million and we...
Story provided by StockMarketWire.com
/* */ RNS Number : 9287I PuriCore Plc 31 March 2015 PuriCore plc ("PuriCore" or the "Group") Final Results for the Year Ended 31 December 2014 A Year of Significant Change 31 March 2015 - PuriCore plc (AIM:...
Register now for FREE PuriCore company news
PuriCore specializes in developing and commercializing solutions to protect against the spread of infectious pathogens. Our proprietary products are effective while being completely safe for human and animal health and the environment. PuriCore has broad experience in key markets that...
This one has come to my attention after a sudden surge from the bottom of its price range. In the last two weeks, PURI has announced US FDA approval to market its Sterilox Endoscopy High-Level Disinfectant System as a medical device in the US; also announced first prelims showing increasing...
Register now for FREE PuriCore share price discussions